Takeda Pharmaceutical
Melitta Bilban-Jaksche serves as Vice President and Global Program Lead for Plasma-Derived Therapies at Takeda since January 2019, overseeing a pipeline of global programs in Hematology, Immunology, Neurology, and Critical Care. Prior to this role, Melitta held positions including Global Program Lead at Takeda, focusing on Hematology and Immunology, and leadership roles at Shire and Baxter, handling clinical development and due diligence for high-priority programs. Melitta's academic background includes a Ph.D. in Organic Chemistry from Scripps Research and a Dipl.Ing. in Technical Chemistry from Technische Universität Wien.
This person is not in any teams
This person is not in any offices
Takeda Pharmaceutical
177 followers
For more than 230 years, Takeda has brought hope to people around the world through its people-centered and innovation-driven approach to science and medicine. As a global pharmaceutical leader, Takeda focuses on solving unmet needs where it can make a real difference—and on putting patients first. Its therapeutics focus is oncology, gastroenterology, and the central nervous system, as well as vaccines.